Assessing favipiravir impact on SARS-CoV-2 transmission within households: Insights from a multi-center study (FaviPrev) Authors: Taweegrit Siripongboonsitti, Marisa Muadchimkaew, Kriangkrai Tawinprai, Ornisa Issaranon, Wichuda Meepholkij, Pureepat Arttawejkul, Apiradee Vararungzarit, Onwalee Dhissayakamol, Wilaiporn Preeyachit, Kamonwan Soonklang, Nithi Mahanonda Published: 2024 ABSTRACT AbstractBackgroundWhile certain studies have demonstrated that antiviral treatment administered to index patients with influenza can mitigate the transmission within households, the efficacy of anti-SARS-CoV-2 agents in curtailing household transmission remains to be conclusively established.MethodsA retrospective study conducted from April 2021 to May 2022 across multiple centers in Thailand compared 892 individuals treated with favipiravir to 84 who received standard treatment among mild to moderate COVID-19 index patients. The study focused on the impact of favipiravir treatment in reducing household SARS-CoV-2 transmission by examining the secondary attack rate.ResultsFavipiravir significantly reduced household SARS-CoV-2 transmission, comparing 1836 household contacts with favipiravir-treated index cases to 170 contacts whose index cases received standard care. Favipiravir led to a 58 % secondary attack rate, substantially lower than the 71.8 % observed with standard treatment, representing a 54 % reduction in transmission likelihood, with an odds ratio of 0.46 (95 % confidence interval [CI] [0.23–0.89]). Index cases treated with favipiravir also demonstrated a relative risk reduction of 0.19 in transmission (95 % CI [0.11–0.27]). Remarkably, favipiravir effectiveness was most notable in unvaccinated index cases, those with symptomatic infections, individuals living in shared spaces like dormitories, flats, or apartments, and those not adhering to mask-wearing within their households.ConclusionsFavipiravir has demonstrated in this study an indirect role in reducing household SARS-CoV-2 transmission, showing notable efficacy in symptomatic and unvaccinated index cases. This breakthrough highlights its potential in broader public health strategies. Exploring the roles and challenges of other anti-SARS-CoV-2 agents remains a vital goal in ongoing research.Keywords: Household transmission, Favipiravir, Anti-SARS-CoV-2, COVID-19, Secondary infection Introduction The coronavirus disease 2019 (COVID-19) is still of global concern in the post-pandemic era, which had resulted in considerable mortality rates worldwide. During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in Spain, a seroprevalence study found that 31 % of confirmed COVID-19 cases involved individuals who had been in contact with infected household members, representing the majority of contact histories.1 In England, studies have noted the secondary infection rate within households to range between 4 and 6.4 per 100 households.2 A comprehensive systematic review indicates an average secondary infection rate of approximately 17 % (4 %–45 %).3 Notably, the secondary attack rate (SAR) escalated to 31.1 % during the outbreak of the B.1.617.2 variant. In Thailand, within-household transmission has been notably high, reaching as much as 56 %.3, 4, 5, 6 Despite over three years since COVID-19 transitioned from a pandemic to an endemic phase, there remains a scarcity of studies focusing on strategies to prevent household transmission. Recent studies have also shown that both inactivated, ChAdOx-1 nCoV, mRNA-accinated index individuals reduced within-household transmission.7 Recent human studies have not yet demonstrated the effectiveness of anti-SARS-CoV-2 treatments in preventing within-household transmission of the virus. However, animal model studies offer some insights. Experiments in female ferrets revealed that a treatment regimen of 100 mg/kg of nirmatrelvir/ritonavir (Nmr) and 5 mg/kg molnupiravir led to a rapid decrease in infectious viral titers and effectively suppressed transmission to untreated, naïve contacts. Notably, this reduction in transmission was observed across all molnupiravir dosage groups, including the lowest dose of 1.25 mg/kg.8 Despite growing concerns over potential shortages in drug supply, there remains a paucity of studies investigating the role of chemoprophylaxis, specifically the use of molnupiravir.9 The use of antiviral medications has been indirectly beneficial in diminishing infectivity and curtailing household transmission, particularly in the context of influenza spread.10 Studies have highlighted the efficacy of neuraminidase inhibitors such as oseltamivir and zanamivir, adamantanes, and the Cap-dependent endonuclease inhibitor baloxavir marboxil (BXM) as potent anti-influenza agents. Their effectiveness supports their deployment in preventing influenza transmission within household settings.10 Specifically, the use of adamantanes (amantadine and rimantadine) in all household members diagnosed with influenza has been associated with a 30 % reduction in the overall incidence of infection compared to placebo. However, randomized controlled trials (RCTs) of rimantadine treatment have not demonstrated a significant reduction in SAR in households treated with rimantadine compared to placebo, a discrepancy attributed to the development of rimantadine resistance.11,12 Studies have shown that early treatment with oseltamivir is associated with a lower SAR. Specifically, initiating oseltamivir at an early stage of the infection results in a SAR of 4.6–7%, compared to 8.7 % when no antiviral is used.13 A randomized controlled trial conducted in crowded, low-income settings revealed that oseltamivir treatment reduced household influenza transmission by 77 % compared to placebo.14 Furthermore, initiating oseltamivir treatment within 120 h after the onset of symptoms in the index patient significantly reduced the number of secondary cases among household contacts.15 In comparison, the secondary household infection rates for index patients treated with laninamivir and zanamivir were 11 % and 11.6 %, respectively, both lower than the 14.6 % observed in the oseltamivir group.16 Additionally, a study using a health insurance claim database has indicated that BXM led to a lower rate of household transmission (17.98 %) compared to oseltamivir (24.16 %). Notably, inhaled zanamivir showed a lower adjusted odds ratio (aOR) of 0.93 (95 % confidence interval [CI]: 0.89–0.97) compared to BXM.17 Favipiravir (FPV), an inhibitor of the RNA-dependent RNA polymerase, has demonstrated activity against SARS-CoV-2 infection and has been used for COVID-19 treatment in Thailand during the pandemic. It has been recognized for its safety profile and association with clinical improvement.18, 19, 20, 21, 22, 23 Although a recent meta-analysis demonstrated unclear benefits of FPV treatment,24 there was concern regarding its non-linear pharmacokinetics and auto-inhibition properties, which might reduce effectiveness in overweight or obese patients, especially in cases treated with inadequate dosing regimens. Numerous randomized trials and real-world studies, particularly in Thailand, have shown that FPV is associated with clinical improvements, preventing deterioration to severe COVID-19, reduced hospitalization, and decreased need for supplemental oxygen.18, 19, 20,25, 26, 27, 28 Similarly, many recent studies and systematic reviews have demonstrated the effectiveness of FPV in reducing hospitalizations, facilitating rapid virologic clearance, and promoting greater clinical improvement.19, 20, 21,29, 30, 31 This study was designed to investigate the effects of FPV administration in mild to moderate COVID-19 index cases, specifically focusing on its potential to prevent within-household SARS-CoV-2 transmission. Methods A multi-center, retrospective study was conducted across three hospitals in Thailand: Chulabhorn Hospital, and Thainakarin Hospital in Bangkok, and Bang Pa-In Hospital in Phra Nakhon Sri Ayutthaya. The study involved 34,004 patients who had survived confirmed COVID-19 between April 1, 2021, and May 31, 2022. Data was extracted from medical records, with additional information on secondary infections and details of household contacts gathered through electronic questionnaires. This study focused on patients with mild to moderate illness. The method in our study followed the STROBE guidelines. All participants provided informed consent. The study followed the Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The Chulabhorn Research Institute Ethics Committee, Human Research, approved the study (approval number 148/2564). Participants Among 16,579 patients with mild to moderate COVID-19, all cases were confirmed by SARS-CoV-2 polymerase chain reaction (PCR) or antigen testing from upper respiratory tract specimens. These patients were managed on an outpatient basis, including home isolation. The study excluded some participants for several reasons: those who declined to provide informed consent or to complete questionnaires; those who had received agents with potential anti-SARS-CoV-2 activity; individuals living alone, as they did not meet the criteria for household transmission analysis; those who were not eligible as index cases or in households with more than one index case. Additionally, index patients who had been treated with COVID-19 convalescent plasma or neutralizing monoclonal antibodies were excluded from the primary analysis. Consequently, 976 index patients were included in the primary analysis, comprising 892 who had received FPV and 84 who had received standard treatment (Fig. 1). Flow chart of patients enrollment. Close contact households were defined as individuals residing within a 6-feet proximity to the index cases for a minimum duration of 10 min over the preceding 14 days, provided that no other suspected index cases were present. The criteria for secondary household infection adhered to the definitions set by the World Health Organization in 2020.32 Confirmed cases within these close-contact households were identified through the history of positive results from either RT-PCR or SARS-CoV-2 antigen rapid diagnostic tests, irrespective of symptom presence. All household contacts and secondary case data were gathered via questionnaires, and no proactive screening interventions among asymptomatic household contacts were performed. Treatment FPV is designated as the primary antiviral treatment for mild to moderate COVID-19 cases according to the Thai National COVID-19 Treatment Guidelines.33 For patients in the FPV-treated group, the protocol involves administering an initial loading dose of 3600 mg on the first day, followed by a maintenance dose of 1600 mg daily for the next four days. It is important to note that patients with obesity, characterized by a body mass index (BMI) exceeding 35 kg/m2, were prescribed a higher initial dose of 4800 mg on the first day, followed by 2000 mg daily for the subsequent four days. The standard treatment group was defined as patients who had received only symptomatic and supportive care without antiviral agents. Primary outcome The primary outcome of this study was the SAR among close household contacts exposed to SARS-CoV-2 infected index cases who received FPV compared to those who received standard treatment. Secondary outcomes This study investigates the characteristics associated with household transmission of the SARS-CoV-2 virus. Specifically, it examines the impact of early FPV administration within the first five days on household transmission. The analysis is further stratified to assess how different household factors contribute to the transmission dynamics. Post-hoc analysis The study conducted a post-hoc analysis of the SAR and aOR to understand the effects of additional treatments, including neutralizing monoclonal antibodies and COVID-19 convalescent plasma, beyond standard care and FPV. This analysis aimed to support hypotheses and improve understanding of how these treatments help prevent household transmission of SARS-CoV-2. Statistical analysis This study evaluated the secondary attack rate (SAR) among household contacts based on whether the index case received FPV. Secondary infections were identified, and SAR for each group was calculated using the number of new cases among susceptible contacts. Relative risk reduction (RRR) measured the percentage reduction in relative risk for each treatment compared to the standard treatment. Data normality was checked with the Shapiro-Wilk test. Categorical data and baseline characteristics were analyzed using the chi-square or Fisher's exact test, while continuous variables were examined with independent t-tests for parametric data and the Mann-Whitney U test for non-parametric data. To detect a 50 % SAR reduction between standard treatment and the FPV group, a sample size of 234 household contacts was required, ensuring 99 % power and an alpha error of 0.05. Non-normally distributed continuous data is presented as medians with interquartile ranges (IQR) and analyzed using the Mann-Whitney U test. The relationship between FPV and standard treatment among index cases was assessed using odds ratios (OR) and adjusted OR (aOR) via multilevel logistic regression to account for the hierarchical data structure, with household contacts nested within households. Fixed effects included confounders such as age, sex, and health conditions, and random effects captured household variations. Statistical significance was set at a two-sided P-value of less than 0.05. All analyses were conducted using Stata/SE version 16.1 (StataCorp, College Station, TX, USA). Results Baseline characteristics In the study, 1836 household contacts linked to index patients treated with FPV and 170 household contacts associated with index patients receiving standard treatment were analyzed (Fig. 1). Among the 976 participants, 892 were index cases treated with FPV, and 84 received standard treatment. There were no significant differences in sex, age, vaccine doses, vaccination status, or time elapsed since the last vaccine dose between the two groups. However, The FPV group had more comorbidities, higher usage of Coronavac and ChAdOx-1 nCoV vaccines, more index cases in August 2021, and a greater number of non-wearing masks at home individuals. Conversely, fewer cases in this group had unknown severity, sore throat, heterologous or mRNA vaccine history, and numbers of index cases in March 2022. The majority of family members in the study ranged from 3 to 4 persons, and there was no significant difference in household size between the groups receiving FPV and those receiving standard treatment (Table 1, Supplementary Table S1). Table 1Baseline characteristics of index cases.Table 1Baseline characteristicsTotalStandard treatmentFavipiravirP-valuePrimary case (index), N97684(8.61)892(91.39)Male, N (%)415(42.52)30(35.71)385(43.16)0.187aAge (years) [median, IQR)]43(33–54)40(33.5–47.5)43(32–53)0.123cAge range of index cases (years), N (%)0.137a•≤ 108(0.82)1(1.19)7(0.78)•11-2024(2.46)1(1.19)23(2.58)•21-30177(18.14)14(16.67)163(18.27)•31-40238(24.39)28(33.33)210(23.54)•41-50245(25.10)25(29.76)220(24.66)•51-60159(16.29)12(14.29)147(16.48)•61-7082(8.40)2(2.38)80(8.97)•>7043(4.41)1(1.19)42(4.71)Comorbidities, N (%)276(28.28)14(16.67)262(29.37)<0.001a•Diabetes mellitus63(6.45)2(2.38)61(6.84)0.112a•Hypertension125(12.81)7(8.33)118(13.23)0.199a•Obesity41(4.20)1(1.19)40(4.48)0.249b•Cerebrovascular disease13(1.33)1(1.19)12(1.35)1.000b•Coronary artery disease14(1.43)014(1.57)0.624b•Asthma11(1.13)011(1.23)0.613b•Malignancy32(3.28)032(3.59)0.103b•Chronic kidney disease7(0.72)07(0.78)1.000b•Chronic liver disease8(0.82)1(1.19)7(0.78)0.515b•HIV infection1(0.10)01(0.11)1.000b•Receiving immunosuppressive agents1(0.10)01(0.11)1.000bSeverity, N (%)<0.001a•Unknown125(12.81)24(28.57)101(11.32.)<0.001•Mild COVID-19643(65.88)60(71.43)583(65.36)0.256•Moderate COVID-19208(21.31)0208(23.32)–Doses of vaccination [median, IQR]2(1.00–3.00)3(2.00–3.00)2(1.00–3.00)0.063cFully vaccination or heterologous vaccination, N (%)0.157a•Unvaccinated175(17.99)11(13.10)164(18.45)•Partial vaccinated136(13.98)8(9.52)128(14.40)•Fully vaccinated or heterologous vaccination662(68.04)65(77.38)597(67.15)Duration from last vaccination, N (%)0.184a•Unvaccinated175(18.50)11(13.25)164(19.00)•< 14 days96(10.15)7(8.43)89(10.31)•15–30 days61(6.45)10(12.05)51(5.91)•31–45 days91(9.62)11(13.25)80(9.27)•46–60 days102(10.78)11(13.25)91(10.54)•61–90 days128(13.53)14(16.87)114(13.21)•91–120 days178(18.82)10(12.05)168(19.47)•121–150 days46(4.86)5(6.02)41(4.75)•151–180 days34(3.59)3(3.61)31(3.59)•> 180 days35(3.70)1(1.20)34(3.94)Types of vaccination, N (%)0.003a•Unvaccinated176(18.09)12(14.29)164(18.45)0.346•Received one dose of vaccinated123(12.64)3(3.57)120(13.50)0.009•Homologous vaccination191(19.63)12(14.29)179(20.13)0.198•Heterologous vaccination483(49.64)57(67.86)426(47.92)0.001The type of vaccines in last vaccination, N (%)<0.001a•Coronavac91(11.40)2(2.74)89(12.28)0.015•ChAdOx-1 nCoV306(38.35)18(24.66)288(39.72)0.012•BBIBP-CorV27(3.38)3(4.11)24(3.31)0.719•BNT162b2298(37.34)33(45.21)265(36.55)0.145•mRNA-127376(9.52)17(23.29)59(8.14)<0.001Symptoms, N (%)0.079a•Asymptomatic101(10.35)4(4.76)97(10.87)•Symptomatic875(89.65)80(95.24)795(89.13)Symptoms presented on the first day, N (%)•Fever608(62.30)45(53.57)563(63.12)0.084a•Cough701(71.82)59(70.24)642(71.97)0.735a•Sore throat672(68.85)66(78.57)606(67.94)0.044aPeriod of infection, N (%)<0.001a•April 20211(0.10)01(0.11)0.334•May 202110(1.02)010(1.12)0.330•June 202124(2.46)024(2.69)0.128•July 2021124(12.70)7(8.33)117(13.12)0.208•August 2021179(18.34)2(2.38)177(19.84)<0.001•September 202122(2.25)1(1.19)21(2.35)0.493•October 20217(0.72)3(3.57)4(0.45)0.001•November 20211(0.10)01(0.11)0.761•December 20212(0.20)02(0.22)0.667•January 202215(1.54)2(2.38)13(1.46)0.513•February 202241(4.20)7(8.33)34(3.81)0.048•March 2022372(38.11)52(61.90)320(35.87)<0.001•April 2022171(17.52)10(11.90)161(18.05)0.156•May 20227(0.72)07(0.78)0.417Duration from onset of symptoms or self-testing in asymptomatic cases to treatment, N (%)0.083a•Asymptomatic220(22.54)25(29.76)195(21.86)•0–24 h231(23.67)24(28.57)207(23.21)•24–48 h247(25.31)21(25.00)226(25.34)•48–72 h121(12.40)8(9.52)113(12.67)•>72 h157(16.09)6(7.14)151(16.93)Duration from last dose vaccination to onset of illness, N (%)0.657a•Within 14 days after the last dose102(12.99)7(9.72)95(13.32)•14–90 days after the last dose463(58.98)43(59.72)420(58.91)•91–180 days after the last dose220(28.03)22(30.56)198(27.77)Number of family members, N (%)0.637a•≤ 2308(31.56)27(32.14)281(31.50)•3-4391(40.06)38(45.24)353(39.57)•5-6189(19.36)13(15.48)176(19.73)•>688(9.02)6(7.14)82(9.19)Mask wearing, N (%)0.043a•Not wearing mask404(41.39)26(30.95)378(42.38)0.042•Occasionally191(19.57)24(28.57)167(18.72)0.030•Every time381(39.04)34(40.48)347(38.90)0.777Abbreviations: N: Number, IQR: Interquartile range.aChi-square test.bFisher's exact test.cMann-Whitney U test. Baseline characteristics of index cases. •≤ 10 ≤ 10 •11-20 11-20 •21-30 21-30 •31-40 31-40 •41-50 41-50 •51-60 51-60 •61-70 61-70 •>70 >70 •Diabetes mellitus Diabetes mellitus •Hypertension Hypertension •Obesity Obesity •Cerebrovascular disease Cerebrovascular disease •Coronary artery disease Coronary artery disease •Asthma Asthma •Malignancy Malignancy •Chronic kidney disease Chronic kidney disease •Chronic liver disease Chronic liver disease •HIV infection HIV infection •Receiving immunosuppressive agents Receiving immunosuppressive agents •Unknown Unknown •Mild COVID-19 Mild COVID-19 •Moderate COVID-19 Moderate COVID-19 •Unvaccinated Unvaccinated •Partial vaccinated Partial vaccinated •Fully vaccinated or heterologous vaccination Fully vaccinated or heterologous vaccination •Unvaccinated Unvaccinated •< 14 days < 14 days •15–30 days 15–30 days •31–45 days 31–45 days •46–60 days 46–60 days •61–90 days 61–90 days •91–120 days 91–120 days •121–150 days 121–150 days •151–180 days 151–180 days •> 180 days > 180 days •Unvaccinated Unvaccinated •Received one dose of vaccinated Received one dose of vaccinated •Homologous vaccination Homologous vaccination •Heterologous vaccination Heterologous vaccination •Coronavac Coronavac •ChAdOx-1 nCoV ChAdOx-1 nCoV •BBIBP-CorV BBIBP-CorV •BNT162b2 BNT162b2 •mRNA-1273 mRNA-1273 •Asymptomatic Asymptomatic •Symptomatic Symptomatic •Fever Fever •Cough Cough •Sore throat Sore throat •April 2021 April 2021 •May 2021 May 2021 •June 2021 June 2021 •July 2021 July 2021 •August 2021 August 2021 •September 2021 September 2021 •October 2021 October 2021 •November 2021 November 2021 •December 2021 December 2021 •January 2022 January 2022 •February 2022 February 2022 •March 2022 March 2022 •April 2022 April 2022 •May 2022 May 2022 •Asymptomatic Asymptomatic •0–24 h 0–24 h •24–48 h 24–48 h •48–72 h 48–72 h •>72 h >72 h •Within 14 days after the last dose Within 14 days after the last dose •14–90 days after the last dose 14–90 days after the last dose •91–180 days after the last dose 91–180 days after the last dose •≤ 2 ≤ 2 •3-4 3-4 •5-6 5-6 •>6 >6 •Not wearing mask Not wearing mask •Occasionally Occasionally •Every time Every time Abbreviations: N: Number, IQR: Interquartile range. Chi-square test. Fisher's exact test. Mann-Whitney U test. Regarding the demographics of household close contacts, there were no notable differences in age, vaccination status, residence type, family structure, living arrangements of post-index case positivity, family size, daily activities, or cohabitation duration with index cases between FPV and standard treatment recipients (Table 2, Supplementary Table S2). Table 2Baseline characteristics of household contacts.Table 2CharacteristicsTotalIndex Patients Who Received Standard treatmentIndex Patients Who Received FavipiravirP-valueTotal household contacts, N20061701836Duration of infected household after contact with index [median, (IQR)]2(1·00–4·00)2(1·00–4·00)2(1·00–3·00)0·687bAge range of household contacts (year-old), N (%)0·198a•<5121(6·30)9(5·77)112(6·34)•5-10149(7·75)17(10·90)132(7·47)•11-20227(11·81)14(8·97)213(12·06)•21-30423(22·01)27(17·31)396(22·42)•31-40378(19·67)37(23·72)341(19·31)•41-50224(11·65)23(14·74)201(11·38)•51-60127(6·61)5(3·21)122(6·91)•61-70168(8·74)15(9·62)153(8·66)•>70105(5·46)9(5·77)96(5·44)Vaccination status, N (%)0·621a•Unvaccinated646(33·80)57(36·31)589(33·58)•Received 1 dose of vaccine within 14 days123(6·44)10(6·37)113(6·44)•Received 1 dose of vaccine more than 14 days227(11·88)15(9·55)212(12·09)•2 doses of homologous vaccination within 14 days155(8·11)16(10·19)139(7·92)•2 doses of homologous vaccination >14 days208(10·88)14(8·92)194(11·06)•2 doses of heterologous vaccination within 14 days17(0·89)017(0·97)•2 doses of heterologous vaccination >14 days53(2·77)4(2·55)49(2·79)•3 doses of heterologous vaccination within 14 days121(6·33)14(8·92)107(6·10)•3 doses of heterologous vaccination >14 days361(18·89)27(17·20)334(19·04)Types of residences, N (%)0·2222•Single-family home402(41·19)33(39·29)369(41·37)•Condominium94(9·63)11(13·10)83(9·30)•Dormitory46(4·71)2(2·38)44(4·93)•Rental room71(7·27)10(11·90)61(6·84)•Flat or Apartment52(5·33)2(2·38)50(5·61)•Townhouse/Townhome/Shop house/Commercial building300(30·74)24(28·57)276(30·94)•Government official residence/Duplex house11(1·13)2(2·38)9(1·01)Coexistence within a family structure, N (%)0·552a•Married couple with offspring living separately30(4·42)5(6·10)25(4·19)•Only husband and wife145(21·39)18(21·95)127(21·31)•A married couple, and 1–2 children217(32·01)27(32·93)190(31·88)•A married couple, and 3–4 children82(12·09)11(13·41)71(11·91)•A married couple, and 5–6 children27(3·98)1(1·22)26(4·36)•A married couple, and ≥6 children4(0·59)04(0·67)•Extended family structure, 3–4 members19(2·8)2(2·44)17(2·85)•Extended family structure, 5–7 members27(3·98)3(3·66)24(4·03)•Extended family structure, 8–10 members9(1·33)1(1·22)8(1·34)•Extended family structure, >10 members2(0·29)02(0·34)•Multi-generational household, 3–4 members29(4·28)4(4·88)25(4·19)•Multi-generational household, 5–7 members45(6·64)4(4·88)41(6·88)•Multi-generational household, 8–10 members4(0·59)04(0·67)•Multi-generational household, >10 members5(0·75)05(0·84)•Residence exclusively for adults, 3–4 individuals30(4·42)4(4·88)26(4·36)•Residence exclusively for adults, 5–7 individuals3(0·44)2(2·44)1(0·17)Living arrangements before index case tests positive, N (%)0·334a•Sharing a bedroom, separate bathrooms52(5·33)7(8·33)45(5·04)•Sharing both the bedroom and bathroom445(45·59)41(48·81)404(45·29)•Separate bedrooms and bathrooms281(28·79)24(28·57)257(28·81)•Separate bedrooms, sharing a bathroom198(20·29)12(14·29)186(20·85)Living arrangements after index case tests positive, N (%)0·139a•Sharing a bedroom, separate bathrooms136(13·93)17(20·24)119(13·34)•Sharing both the bedroom and bathroom169(17·32)18(21·43)151(16·93)•Separate bedrooms and bathrooms510(52·25)35(41·67)475(53·25)•Separate bedrooms, sharing a bathroom161(16·50)14(16·67)147(16·48)Number of household contacts, N (%)0·8682•≤ 2706(72·34)61(72·62)645(72·31)•3-4211(21·62)17(20·24)194(21·75)•5-641(4·20)4(4·76)37(4·15)•>618(1·84)2(2·38)16(1·79)Number of household contacts who negative for COVID-19 testing, N (%)0·1202•≤ 2837(85·76)79(94·05)758(84·98)•3-498(10·04)3(3·57)95(10·65)•5-628(2·87)2(2·38)26(2·91)•>613(1·33)013(1·46)Household routines (Before index positive testing), N (%)•Eating meals together544(78·16)60(71·43)484(79·08)0·111a•Sharing personal items305(43·82)39(46·43)266(43·46)0·608a•Sharing a bathroom565(81·18)64(76·19)501(81·86)0·212a•Living/staying in the same room with more than one person695(99·86)84(100)611(99·84)1·0002•Wearing a mask when in shared areas449(64·51)60(71·43)389(63·56)0·158a•Cleaning commonly touched surfaces such as doorknobs, tables, and stair railings at least once a day322(46·26)44(52·38)278(45·42)0·231a•Handwashing with alcohol-based sanitizer inside the house562(80·75)66(78·57)496(81·05)0·590aHousehold routines (After index positive testing), N (%)•Eating meals together95(13·65)14(16·67)81(13·24)0·390a•Sharing personal items79(11·35)15(17·86)64(10·46)0·045a•Sharing a bathroom280(40·23)39(46·43)241(39·38)0·217a•Living/staying in the same room with more than one person214(30·75)30(35·71)184(30·07)0·293a•Wearing a mask when in shared areas588(84·48)67(79·76)521(85·13)0·203a•Cleaning commonly touched surfaces such as doorknobs, tables, stair railings at least once a day522(75·00)70(83·33)452(73·86)0·060a•Handwashing with alcohol-based sanitizer inside the house615(88·36)75(89·29)540(88·24)0·778aDuration per day of cohabitation with a household member infected with COVID-19, N (%)0·751a•1–6 h145(24·13)21(29·17)124(23·44)•7–12 h244(24·13)28(38·89)216(40·83)•13–18 h116(19·30)13(18·06)103(19·47)•19–24 h96(15·97)10(13·89)86(16·26)Daily duration of cohabitation among household members who are not infected with COVID-19, N (%)0·366a•1–6 h76(31·15)12(42·86)64(29·63)•7–12 h53(21·72)3(10·71)50(23·15)•13–18 h19(7·79)2(7·14)17(7·87)•19–24 h96(39·34)11(39·29)85(39·35)Abbreviation: N: Number; IQR: Interquartile range.aChi-square test.bMann-Whitney U test. Baseline characteristics of household contacts. •<5 <5 •5-10 5-10 •11-20 11-20 •21-30 21-30 •31-40 31-40 •41-50 41-50 •51-60 51-60 •61-70 61-70 •>70 >70 •Unvaccinated Unvaccinated •Received 1 dose of vaccine within 14 days Received 1 dose of vaccine within 14 days •Received 1 dose of vaccine more than 14 days Received 1 dose of vaccine more than 14 days •2 doses of homologous vaccination within 14 days 2 doses of homologous vaccination within 14 days •2 doses of homologous vaccination >14 days 2 doses of homologous vaccination >14 days •2 doses of heterologous vaccination within 14 days 2 doses of heterologous vaccination within 14 days •2 doses of heterologous vaccination >14 days 2 doses of heterologous vaccination >14 days •3 doses of heterologous vaccination within 14 days 3 doses of heterologous vaccination within 14 days •3 doses of heterologous vaccination >14 days 3 doses of heterologous vaccination >14 days •Single-family home Single-family home •Condominium Condominium •Dormitory Dormitory •Rental room Rental room •Flat or Apartment Flat or Apartment •Townhouse/Townhome/Shop house/Commercial building Townhouse/Townhome/Shop house/Commercial building •Government official residence/Duplex house Government official residence/Duplex house •Married couple with offspring living separately Married couple with offspring living separately •Only husband and wife Only husband and wife •A married couple, and 1–2 children A married couple, and 1–2 children •A married couple, and 3–4 children A married couple, and 3–4 children •A married couple, and 5–6 children A married couple, and 5–6 children •A married couple, and ≥6 children A married couple, and ≥6 children •Extended family structure, 3–4 members Extended family structure, 3–4 members •Extended family structure, 5–7 members Extended family structure, 5–7 members •Extended family structure, 8–10 members Extended family structure, 8–10 members •Extended family structure, >10 members Extended family structure, >10 members •Multi-generational household, 3–4 members Multi-generational household, 3–4 members •Multi-generational household, 5–7 members Multi-generational household, 5–7 members •Multi-generational household, 8–10 members Multi-generational household, 8–10 members •Multi-generational household, >10 members Multi-generational household, >10 members •Residence exclusively for adults, 3–4 individuals Residence exclusively for adults, 3–4 individuals •Residence exclusively for adults, 5–7 individuals Residence exclusively for adults, 5–7 individuals •Sharing a bedroom, separate bathrooms Sharing a bedroom, separate bathrooms •Sharing both the bedroom and bathroom Sharing both the bedroom and bathroom •Separate bedrooms and bathrooms Separate bedrooms and bathrooms •Separate bedrooms, sharing a bathroom Separate bedrooms, sharing a bathroom •Sharing a bedroom, separate bathrooms Sharing a bedroom, separate bathrooms •Sharing both the bedroom and bathroom Sharing both the bedroom and bathroom •Separate bedrooms and bathrooms Separate bedrooms and bathrooms •Separate bedrooms, sharing a bathroom Separate bedrooms, sharing a bathroom •≤ 2 ≤ 2 •3-4 3-4 •5-6 5-6 •>6 >6 •≤ 2 ≤ 2 •3-4 3-4 •5-6 5-6 •>6 >6 •Eating meals together Eating meals together •Sharing personal items Sharing personal items •Sharing a bathroom Sharing a bathroom •Living/staying in the same room with more than one person Living/staying in the same room with more than one person •Wearing a mask when in shared areas Wearing a mask when in shared areas •Cleaning commonly touched surfaces such as doorknobs, tables, and stair railings at least once a day Cleaning commonly touched surfaces such as doorknobs, tables, and stair railings at least once a day •Handwashing with alcohol-based sanitizer inside the house Handwashing with alcohol-based sanitizer inside the house •Eating meals together Eating meals together •Sharing personal items Sharing personal items •Sharing a bathroom Sharing a bathroom •Living/staying in the same room with more than one person Living/staying in the same room with more than one person •Wearing a mask when in shared areas Wearing a mask when in shared areas •Cleaning commonly touched surfaces such as doorknobs, tables, stair railings at least once a day Cleaning commonly touched surfaces such as doorknobs, tables, stair railings at least once a day •Handwashing with alcohol-based sanitizer inside the house Handwashing with alcohol-based sanitizer inside the house •1–6 h 1–6 h •7–12 h 7–12 h •13–18 h 13–18 h •19–24 h 19–24 h •1–6 h 1–6 h •7–12 h 7–12 h •13–18 h 13–18 h •19–24 h 19–24 h Abbreviation: N: Number; IQR: Interquartile range. Chi-square test. Mann-Whitney U test. Impact of favipiravir on secondary attack rate FPV treatment significantly reduced the SAR among index cases. The SAR decreased to 58 % for those treated with FPV compared to 71.8 % under standard treatment, representing a RRR of 0.19 (95%CI [0.11–0.27], p = 0.001; OR 0.46, 95%CI [0.23–0.89]). The reduction was notably stronger in unvaccinated individuals (p = 0.002; OR 0.11, 95%CI [0.02–0.53]) and symptomatic index cases (p = 0.002; OR 0.46, 95%CI [0.22–0.97]) those displaying symptoms like fever, cough, and sore throat. The effectiveness of FPV varied significantly across different demographic segments and living conditions. Notably, it was highly effective in reducing transmission among the 41–60-year age group (OR 0.09, p < 0.001, 95%CI [0.02–0.43]). Similarly, it showed substantial effectiveness for those living in dormitories or rental rooms (OR 0.10, p < 0.001, 95%CI [0.02–0.44]), households with fewer than four contacts (OR 0.51, p < 0.003, 95%CI [0.26–0.97]), and among individuals who did not wear masks (OR 0.31, p = 0.007, 95%CI [0.10–0.94]) (Table 3, Fig. 2). Table 3Secondary attack rate, Odds ratio and Relative risk reduction compared between index patients who received favipiravir and received standard treatment stratified with factors related to the transmissibility of index cases.Table 3Factor related to the transmissibility of index casesIndex cases N (%)Household contacts N (%)Secondary cases N (%)Secondary attack rate (%)Odds ratio, OR (95%CI)dRelative Risk Reduction, RRR (95%CI)Index cases received standard treatmentIndex cases received favipiravirP-valueIndex cases received standard treatmentIndex cases received favipiravirP-valuecIndex cases received favipiravirIndex cases received favipiravirNumber of infected household contacts9762006122/1701064/1836<0·001a71·7657·950·0010·46(0·23-0·89)0·19(0·11,0·27)•Asymptomatic infection–184(17·08)18(16·22)166(17·18)–10·599·040·5030·45(0·12-1·75)0·35(0·01,0·57)•Symptomatic infection–893(82·92)93(83·78)800(82·82)–54·7043·570·0050·44(0·21-0·92)0·23(0·12,0·32)Diagnostic methods in household contacts•Positive antigen and PCR–978(91·32)108(98·18)870(90·53)–63·5347·39<0·0010·37(0·18-0·78)0·23(0·14,0·32)•Positive antigen testing–388(36·23)43(39·09)345(35·90)–25·2918·790·0400·31(0·09-1·11)0·35(0·17,0·48)•Positive SARS-CoV-2 PCR–590(55·09)65(59·09)525(54·63)–38·2428·590·0080·32(0·13-0·81)0·30(0·16,0·41)•Symptomatic with negative testing–93(8·68)2(1·82)91(9·47)–1·184·960·0252·46(0·29-20·81)−1·64(-9·39,0·33)Gender•Male415(43·16)839(41·82)44(36·07)439(41·26)0·006a74·5856·280·0060·35(0·11-1·08)0·25(0·11,0·36)•Female561(57·48)1167(58·18)78(63·93)625(58·74)0·023a70·2759·190·0230·54(0·24-1·24)0·16(0·04,0·26)Duration from last dose vaccination to onset of illness•Within 14 days after the last dose102(12·99)120(7·53)11(11·00)55(6·31)0·127a73·3352·380·1270·33(0·04-2·51)0·29(-0·02,0·50)•14–90 days after the last dose463(58·98)1070(67·17)60(60·00)578(66·36)0·253a65·2259·100·2530·91(0·34-2·44)0·09(-0·06,0·23)•91–180 days after the last dose220(28·03)403(25·30)29(29·00)238(27·32)0·057a80·5664·850·0570·52(0·12-2·26)0·19(0·04,0·33)Types of vaccination•Unvaccinated176(18·09)382(19·10)22(18·03)182(17·15)0·002a81·4851·270·0020·11(0·02-0·53)0·37(0·23,0·49)•All vaccination797(81·91)1618(80·90)100(81·97)879(82·85)0·016a69·9359·590·0160·65(0·31-1·39)0·42(0·35,0·49)•Partial or received one dose of vaccinated123(12·64)223(11·15)4(3·28)91(8·58)0·405b66·6741·940·2270·27(0·03-2·71)0·38(-0·12,0·66)•Fully homologous vaccination191(19·63)357(17·85)11(9·02)178(16·78)0·050a78·5751·900·0500·20(0·02-2·01)0·34(0·12,0·51)•Fully heterologous vaccination483(49·64)1038(51·90)85(69·67)610(57·49)0·589a69·1166·670·5891·16(0·49-2·73)0·04(-0·10,0·15)Period of Infection•April 2021–July 2021159(16·29)301(15·00)8(6·56)126(11·84)0·207a61·5443·750·2070·25(0·04-1·53)0·29(-0·11,0·55)•August 2021–December 2021211(21·62)428(21·34)9(7·38)201(18·89)0·068a75·0048·320·0680·13(0·01-1·33)0·36(0·09,0·54)•Jan 2022–May 2022606(62·09)1277(63·66)105(86·07)737(69·27)0·080a72·4165·110·0810·80(0·37-1·75)0·10(-0·003,0·19)Asymptomatic101(10·35)180(8·97)2(1·64)75(7·05)0·577b66·6742·370·3990·24(0·01–9·75)0·36(-0·44,0·72)Symptomatic875(89·65)1826(91·03)120(98·36)989(92·95)0·002a71·8659·610·0020·50(0·26-0·99)0·17(0·08,0·25)•Fever608(62·30)1187(59·17)64(52·46)645(60·62)0·001a77·1158·420·0010·33(0·13-0·82)0·24(0·14,0·33)•Cough701(71·82)1481(73·83)92(75·41)817(76·79)<0·001a77·3159·99<0·0010·33(0·15-0·73)0·22(0·14,0·30)•Sore throat672(68·85)1450(72·28)102(83·61)778(73·12)0·002a72·8659·390·0020·46(0·22-0·97)0·18(0·09,0·27)Duration from onset of symptoms•<48 h478(63·32)965(63·49)53(71·62)537(65·33)0·408a65·4360·750·4080·80(0·33-1·97)0·07(-0·10,0·21)•48–72 h121(16·01)259(17·04)6(8·11)149(18·13)0·744b66·6759·600·6710·72(0·07-7·20)0·11(-0·43,0·44)•>72 h157(20·77)296(19·47)15(20·27)136(16·55)0·240a62·5050·000·2400·42(0·09-2·01)0·20(-0·11,0·43)Factor of household contactsAge range of household contacts (years)•<21–497(25·86)34(31·48)323(31·42)0·053a85·0070·680·0540·38(0·10-1·42)0·17(0·04,0·28)•21-40–801(41·68)41(37·96)416(40·47)0·238a64·0656·450·2380·56(0·23-1·37)0·12(-0·07,0·27)•41-60–351(18·26)24(22·22)165(16·05)<0·001a85·7151·08<0·0010·09(0·02-0·43)0·40(0·28,0·50)•>60–273(14·20)9(8·33)124(12·06)0·250a37·5049·800·2502·09(0·47-9·15)−0·33(-1·26,0·22)Types of residences•Single-family home402(41·19)1002(49·95)41(33·61)527(49·53)0·741a58·5756·550·7421·01(0·32-3·14)0·03(-0·18,0·21)•Condominium94(9·63)127(6·33)14(11·48)69(6·48)0·046a87·5062·160·0460·21(0·02-2·25)0·29(0·10,0·44)•Dormitory, Rental room, Flat or Apartment169(17·31)269(13·41)30(24·59)127(11·94)<0·001a90·9153·81<0·0010·10(0·02-0·44)0·41(0·31,0·50)•Townhouse/Townhome/Building300(30·74)579(28·86)26(21·31)329(30·92)0·620a65·0061·040·6200·71(0·24-2·13)0·06(-0·19,0·26)•Government official residence/Duplex house11(1·13)29(1·45)11(9·02)12(1·13)0·058b100·0066·670·032–0·33(0·08,0·52)Living arrangements after index case tests positive•Sharing a bedroom, separate bathrooms136(13·93)313(15·60)31(25·41)156(14·66)0·584a63·2759·090·5840·48(0·10-2·28)0·07(-0·18,0·26)•Sharing both the bedroom and bathroom169(17·32)244(12·16)25(20·49)157(14·76)0·023a92·5972·350·0230·20(0·03-1·23)0·22(0·11,0·32)•Separate bedrooms and bathrooms510(52·25)1143(56·98)50(40·98)568(53·38)0·007a69·4453·030·0010·60(0·22-1·64)0·24(0·10,0·35)•Separate bedrooms, sharing a bathroom161(16·50)306(15·25)16(13·11)183(17·20)0·432a72·7364·440·4320·52(0·10-2·62)0·11(-0·16,0·32)Number of household contacts•459(6·05)347(17·30)30(24·59)249(23·40)0·046a93·7579·050·0460·30(0·02–3·72)0·16(0·06,0·24)Mask wearing•Not wearing mask404(41·39)779(38·83)31(25·41)411(38·63)0·007a77·5055·620·0070·31(0·10-0·94)0·28(0·14,0·40)•Wearing mask572(58·61)1227(61·17)91(74·59)653(61·37)0·021a70·0059·530·0210·54(0·22-1·30)0·15(0·04,0·25)•Occasionally191(19·57)455(22·68)48(39·34)255(23·97)0·253a72·7365·550·2530·84(0·26-2·75)0·10(-0·06,0·24)•Every time381(39·04)772(38·48)43(35·25)398(37·41)0·089a67·1956·210·0890·38(0·11-1·34)0·16(-0·005,0·30)aChi-square test.bFisher's exact test.cTwo sample tests for Proportions.dMultilevel logistic regression. Secondary attack rate, Odds ratio and Relative risk reduction compared between index patients who received favipiravir and received standard treatment stratified with factors related to the transmissibility of index cases. •Asymptomatic infection Asymptomatic infection •Symptomatic infection Symptomatic infection •Positive antigen and PCR Positive antigen and PCR •Positive antigen testing Positive antigen testing •Positive SARS-CoV-2 PCR Positive SARS-CoV-2 PCR •Symptomatic with negative testing Symptomatic with negative testing •Male Male •Female Female •Within 14 days after the last dose Within 14 days after the last dose •14–90 days after the last dose 14–90 days after the last dose •91–180 days after the last dose 91–180 days after the last dose •Unvaccinated Unvaccinated •All vaccination All vaccination •Partial or received one dose of vaccinated Partial or received one dose of vaccinated •Fully homologous vaccination Fully homologous vaccination •Fully heterologous vaccination Fully heterologous vaccination •April 2021–July 2021 April 2021–July 2021 •August 2021–December 2021 August 2021–December 2021 •Jan 2022–May 2022 Jan 2022–May 2022 •Fever Fever •Cough Cough •Sore throat Sore throat •<48 h <48 h •48–72 h 48–72 h •>72 h >72 h •<21 <21 •21-40 21-40 •41-60 41-60 •>60 >60 •Single-family home Single-family home •Condominium Condominium •Dormitory, Rental room, Flat or Apartment Dormitory, Rental room, Flat or Apartment •Townhouse/Townhome/Building Townhouse/Townhome/Building •Government official residence/Duplex house Government official residence/Duplex house •Sharing a bedroom, separate bathrooms Sharing a bedroom, separate bathrooms •Sharing both the bedroom and bathroom Sharing both the bedroom and bathroom •Separate bedrooms and bathrooms Separate bedrooms and bathrooms •Separate bedrooms, sharing a bathroom Separate bedrooms, sharing a bathroom •4 >4 •Not wearing mask Not wearing mask •Wearing mask Wearing mask •Occasionally Occasionally •Every time Every time Chi-square test. Fisher's exact test. Two sample tests for Proportions. Multilevel logistic regression. The odds ratio comparison of SARS-CoV-2 secondary attack rates among index cases who had received favipiravir vs. standard treatment. The SAR was significantly lower in index cases who had received FPV, although it was not proven to provide a potential preventive effect among vaccinated individuals, those who were symptomatic with negative test results, those living in condominiums, government official residences, or duplex houses, those sharing or having separate bedrooms and bathrooms, households with more than four contacts, and even among individuals who consistently wore masks. Our study did not demonstrate a significant decrease in SAR during outbreaks of different variants of concern in Thailand, including the Alpha variant from April 2021 to July 2021, the Delta variant from August 2021 to December 2021, and the Omicron variant from January 2022 to May 2022. However, there was a significant reduction in the RRR during the Delta variant outbreak period.34 (Table 3, Supplementary Table S10). Subgroup analysis within intra-treatment group The subgroup analysis revealed that index cases treated with FPV experienced a decrease in within-household SARS-CoV-2 transmission, especially among those aged 31–40 and those over 50 years old. However, it also showed an increased risk of infection among household contacts aged 5–10 years compared to those under 5 years old. Additionally, a preventive effect was observed in FPV-treated index cases who had received their first vaccine dose within 14 days compared to unvaccinated patients. In contrast, index cases receiving standard treatment showed a preventive effect in those who had received either one or two doses of a homologous vaccine (Supplementary Table S3). However, a reduction in transmission was noted among vaccinated (between 46 and 60 days post-vaccination) index cases who had received standard treatment compared to unvaccinated ones. Conversely, FPV-treated index cases exhibited an increased risk of transmission, especially in symptomatic cases with symptoms like cough and in those sharing a bedroom and bathroom. Moreover, household contacts who either had received FPV or had not, but were vaccinated with one dose within 14 days, showed a reduced risk of transmission. However, this reduced risk was only observed in those who did not receive FPV and were vaccinated more than 14 days prior. Similarly, household contacts who received three doses of heterologous vaccination more than 14 days prior, or at least two doses of a homologous vaccine, showed a lower transmission risk compared to unvaccinated individuals when the index patients had received standard treatment (Supplementary Table S7). Post-hoc analysis: comparison with other treatments The post-hoc analysis showed a reduction in transmission risk among index cases who had received FPV (RRR 0.19, 95 % CI [0.11, 0.27], p < 0.001). On the other hand, neither neutralizing monoclonal antibodies (Nmab) nor convalescence plasma transfusion (CPT) demonstrated a significant reduction in transmission risk (Nmab: RRR 0.15, 95 % CI [−0.02, 0.30]; CPT: RRR -0.11, 95 % CI [−1.41, 0.54]). SAR was lower among index cases who had received FPV compared to those who received standard treatment, whereas Nmab and CPT treatments showed no significant difference from standard treatment (p = 0.066 and p = 0.326, respectively). Nonetheless, Nmab treatment in index cases with comorbidities, those presenting early symptoms such as fever and cough within 24–48 h, those sharing bedrooms and bathrooms, and household contacts aged 41–50 years, was associated with decreased SAR compared with standard treatment (Supplementary Tables S4.1-4.2, S5, S9.1-9.2). Moreover, the study could not demonstrate the effect of the vaccinated status of index patients on reducing household transmission (Supplementary Table S6). Discussion This study highlights an important aspect of COVID-19 management in reducing within-household transmission through the use of anti-SARS-CoV-2 agents, particularly FPV, in treating index patients. The findings indicate that FPV treatment was associated with a reduction in the SAR from 71.8 % in those receiving standard treatment to 58 %, corresponding to a 54 % lower likelihood of transmission (OR 0.46, 95% CI [0.23–0.89]). Furthermore, there was a 19 % relative risk reduction (RRR) of 0.19 (95% CI [0.11–0.27]), even in the presence of comorbidities and limited adherence to mask-wearing among FPV-treated index patients. The benefits of FPV treatment in index cases for preventing household transmission of COVID-19 were observed in specific groups. These include the previously healthy 41-60 years of age group, responsible for half of symptomatic infections,35 and individuals living in dormitories or rental rooms. These residences are often associated with a higher risk of developing secondary cases and large clusters during outbreaks due to shared living areas.36 Moreover, our study found that FPV-treated index cases prevent household transmission in families with up to four members, and among those not wearing masks, that were at an increased risk of household transmission.4,7 The findings of our study highlight that FPV treatment is most effective in symptomatic index patients, particularly those with fever, cough, and sore throat, and its impact is even more significant in unvaccinated individuals. These results vary among different demographics, health status, and living conditions. The ability of FPV to curb household transmission of COVID-19 can potentially be attributed to its antiviral effects, which include inhibiting SARS-CoV-2 replication and facilitating more rapid improvement of clinical symptoms.19,20,31 Interestingly, our findings align with recent studies suggesting that asymptomatic patients generally transmit the virus less than those in presymptomatic or symptomatic phases. It appears that the benefits of FPV in reducing transmission may be less pronounced in asymptomatic index cases.35,37 In our study, the SAR observed in asymptomatic index patients was 10.6 % for those who received standard treatment and 9 % for those treated with FPV, compared to 54.7 % and 43.6 % in symptomatic cases, respectively. These findings indicate that FPV does not significantly lower transmission risk among asymptomatic patients (Table 3). Our study highlighted a notably high SAR for household transmission in Thailand, exceeding 50 %, which aligns with recent studies within the country.6,7 Several factors typical of Thai cultural practices may influence this elevated SAR. For instance, the prevalent living conditions involve extended family households, with 99 % residing in a limited space, 81 % sharing bathrooms, and 78 % having a meal together. Additionally, 44 % of households share personal items, 39 % of individuals do not wear masks regularly, and 34 % of household members are unvaccinated, all of which likely contribute to the high reproductive number observed in our study (Table 2, Supplementary Table S7). Furthermore, inadequate ventilation and the tendency to mix in small, enclosed spaces with minimal airflow might also significantly increase the SAR in these settings. However, it is important to note that our study did not investigate these specific environmental factors. This underscores the potential of FPV in mitigating the spread of COVID-19 from primary cases within domestic settings and was a critical tool in managing and controlling the spread of SARS-CoV-2, especially in high-risk, close-contact environments like households in high SAR countries. These findings could inform and guide policy decisions, particularly in prioritizing FPV treatment for targeted groups. Adjusting treatment protocols to factor in vaccination status and symptom profiles could be a strategic approach to managing the disease. Our data potentially offer valuable evidence to support public health strategies during widespread, uncontrolled SARS-CoV-2 outbreaks and could effectively reduce the burden on healthcare systems. Recent findings suggest that vaccinated index cases may derive limited benefit from FPV treatment. This could be attributed to the inherent effectiveness of vaccines in reducing household transmission. For instance, a study showed a SAR of 5.7 % in households with ChAdOx1 nCoV-19 vaccinated index cases and 6.2 % with BNT162b2 vaccinated cases.38 Additionally, the effectiveness of BNT162b2 and mRNA-1273 vaccines resulted in a 63 % reduction in transmission among unvaccinated index cases, compared to a 40 % reduction in the vaccinated group.39 Furthermore, the SAR was reported at 50.77 % in unvaccinated index cases and 46.8 % in those who had received the inactivated vaccine or ChAdOx-1 nCoV.7 These findings underscore the complex relationship between vaccination status and the efficacy of treatments like FPV. The impact of vaccination in preventing household transmission may vary based on the period of peak vaccine effectiveness and the proportion of vaccinated individuals within a household, aligning with the concept of herd immunity. This area warrants further research to fully understand these dynamics.40 However, our post hoc study demonstrated that the vaccine did not provide an RRR for preventing household transmission (Supplementary Table S6). The challenging investigation on the role of other treatment modalities and antiviral agents such as nirmaltrelvir/ritonavir, molnupiravir, and remdesivir on index cases could reduce the within-household transmission. Although the post hoc data demonstrated that Nmab and CPT did not significantly reduce SAR compared to FPV, Nmab demonstrated some benefits in specific scenarios, such as decreased transmission in households sharing bedrooms and bathrooms that needs a larger sample and warrants further investigation. However, the research also underscores areas where conclusive evidence is still lacking. The effectiveness of FPV in certain scenarios, such as symptomatic contacts with negative testing, recent vaccinations, and varied vaccination types, remains uncertain. Moreover, the study indicates that while FPV appears to reduce transmission risk significantly, the full extent of its effectiveness in diverse conditions and among different age groups requires further investigation. The use of FPV to prevent household SARS-CoV-2 transmission, especially among individuals without high-risk complications, necessitates careful consideration of potential drug overuse, scarcity, cost-effectiveness, and the risk of developing drug resistance. It is crucial to balance FPV treatment across all index cases, including those with high-risk comorbidities who need it to prevent severe COVID-19 and those in non-high-risk groups. Furthermore, investigating another role for FPV such as post-exposure prophylaxis (PEP) in high-risk contacts, is challenging, including possibly focusing PEP strategies on those at high risk of severe COVID-19 or who are likely to transmit the virus to vulnerable individuals. Our study has several limitations. Firstly, being retrospective, it is subject to potential recall bias, indicating the need for RCTs for more definitive results. Secondly, various factors could affect the SAR, and the sample size in each arm for each factor may be insufficient for comprehensive analysis. Thirdly, the study spanned the outbreak periods of the Alpha, Delta, and Omicron variants, and it remains uncertain whether FPV is effective against newer variants. Fourthly, our study was conducted in Thailand during the outbreak, where FPV was predominantly used as per Thai guidelines for treating mild to moderate COVID-19. This preference led to a smaller sample size of individuals on standard treatment. Additionally, the reliance on questionnaires and the decline by about 15,000 individuals to participate further limited the sample size, potentially influencing the results and endpoints. Fifthly, potential sources of viral positive results among household contacts beyond transmission from the index patient were not investigated. Sixthly, the duration of symptoms among index cases was not collected, although it might affect the length of infectiousness and SAR. Seventhly, our statistical analysis did not adjust for some potential confounders and covariates, such as virus strain, symptoms and duration of symptoms, and type of household. We did not perform sensitivity analysis in relevant subgroups or use matching methods. Eighthly, the small size of the index cases who received standard treatment during the Alpha and Delta variant outbreaks in Thailand and the predominance of comparators during the Omicron variant outbreak might limit the value of our tests. Ninthly, the study relied on questionnaires to collect data on household contacts; thus, asymptomatic individuals who did not undergo SARS-CoV-2 testing may be underreported. Tenthly, the impact of false positive results, particularly from antigen tests, and false negatives from self-administered antigen tests in index cases and household contacts could have affected the outcomes. Finally, while the study demonstrates the benefits of FPV, it does not include an analysis of other antiviral agents despite conducting post-hoc analysis. Conclusions The use of FPV in treating index COVID-19 patients shows a promising indirect effect in reducing the transmission of SARS-CoV-2 within households. This effect is particularly significant among symptomatic and unvaccinated individuals, as well as in household contacts who have high-risk factors for transmission. These insights highlight the critical need for ongoing research to establish the definitive effectiveness of FPV. Additionally, investigating the impact of various anti-SARS-CoV-2 agents in preventing household transmission, particularly when administered to index cases, presents a significant challenge and is a crucial area for further research. CRediT authorship contribution statement Taweegrit Siripongboonsitti: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Marisa Muadchimkaew: Validation, Software, Investigation, Formal analysis, Data curation, Conceptualization. Kriangkrai Tawinprai: Investigation. Ornisa Issaranon: Resources, Investigation. Wichuda Meepholkij: Resources, Investigation. Pureepat Arttawejkul: Resources, Investigation. Apiradee Vararungzarit: Resources, Investigation. Onwalee Dhissayakamol: Resources, Investigation. Wilaiporn Preeyachit: Investigation, Formal analysis, Data curation. Kamonwan Soonklang: Visualization, Validation, Software, Investigation, Funding acquisition, Formal analysis, Data curation. Nithi Mahanonda: Supervision, Investigation. Patient and public involvement Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research. Ethics approval and consent to participate This study was approved by the Ethics Committee for Human Research, Chulabhorn Research Institute (EC No. 148/2564). Consent for publication Not applicable. Availability of data and materials The datasets generated and analyzed during the current study are not publicly available to avoid its use for inappropriate purposes but are available from the corresponding author on reasonable request. Authors' information Not applicable. Declaration of generative AI in scientific writing During the preparation of this work, the authors used ChatGPT4 for the purpose of language editing. After using this tool/service, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication. Funding This study was supported by the Chulabhorn Royal Academy in Bangkok, Thailand. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments We express our profound gratitude to all healthcare providers who dedicatedly served on the frontlines at the Acute Respiratory Tract Infection clinic, the COVID-19 outpatient clinic, and in cohort wards. Their steadfast support and contribution of clinical data were instrumental to the success of this study. We also extend our deepest sympathies and condolences to all the patients and their families who have been impacted by this crisis. Special thanks are owed to Prof. Chusana Suankratay, whose inspiration and encouragement significantly fueled our commitment and guided us towards the presentation and publication of our research. Equally, we are indebted to Prof. Chirayu Auewarakul for his invaluable support in both conducting and publishing this research. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.jve.2024.100576. Supplementary data The following is the Supplementary data to this article: Multimedia component 1 Data availability The data that has been used is confidential. References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement The datasets generated and analyzed during the current study are not publicly available to avoid its use for inappropriate purposes but are available from the corresponding author on reasonable request. The data that has been used is confidential.